1. Percutaneous Radiofrequency Ablation for Intermediate-Stage Hepatocellular Carcinoma.
- Author
-
Kariyama, Kazuya, Wakuta, akiko, Nishimura, Mamoru, Kishida, Masayuki, Oonishi, ayano, Ohyama, atsushi, Nouso, Kazuhiro, and Kudo, Masatoshi
- Subjects
- *
ACADEMIC medical centers , *BIOPSY , *CATHETER ablation , *CONFIDENCE intervals , *CONFERENCES & conventions , *HEPATOCELLULAR carcinoma , *LONGITUDINAL method , *MULTIVARIATE analysis , *REGRESSION analysis , *SAFETY , *SURVIVAL , *TUMOR classification , *TREATMENT effectiveness , *PROPORTIONAL hazards models , *DATA analysis software , *DESCRIPTIVE statistics , *KAPLAN-Meier estimator , *LOG-rank test , *ODDS ratio , *THERAPEUTICS - Abstract
Objectives: Radiofrequency ablation plays a key role in the treatment of early-stage hepatocellular carcinoma. However, it is not recommended for intermediate-stage hepatocellular carcinoma. The objective of this study was to clarify the efficacy and safety of radiofrequency ablation for treating intermediate-stage hepatocellular carcinoma. Methods: We examined the outcome of 65 consecutive patients who were treated with radiofrequency ablation with or without transarterial chemoembolization for intermediate-stage hepatocellular carcinoma. Results: With a median follow-up of 37 months, overall survival rates of 65 cases at 1, 3, 5, and 7 years were 90, 70, 51, and 36%, respectively. Multivariate analysis of clinical parameters revealed that the multicentric occurrence (MC)/intrahepatic metastasis (IM) was the only significant prognostic factor for overall survival (hazard ratio, 4.9; 95% confidence intervals, 2.1-11.4). Tumor size and tumor number were not significant factors for survival. The overall survival rates of patients with MC (n = 33) at 1, 3, 5, and 7 years were 97, 90, 80, and 59%, respectively; those for patients with IM (n = 32) were 86, 55, 14, and 8%, respectively (p < 0.0001). Two cases (4.9%) had complications of hemothorax and diaphragmatic burn; however, no major complications were observed. Conclusion: Radiofrequency ablation is safe and effective for the treatment of intermediate-stage hepatocellular carcinoma, especially for patients with MC. © 2015 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF